NASDAQ:NVLN - Novelion Therapeutics Inc.
$1.35
 $-0.01
-0.74%
2:05PM EDT
2019-02-15
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NVLN     avg for
industry  
  avg for
sector  
42 stocks weight:  16. 73   0. 00   0. 00  
42 stocks rank:  3. 76 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  
mean recommendation:  3. 00   1. 91   1. 93  

quick ratio:  0. 13   5. 37   1. 81  
current ratio:  0. 23   5. 69   2. 19  

ex-dividend date:     2013-06-27
target price low:  2. 07   88. 97   117. 82  
target price avg:  2. 07   115. 19   141. 96  
target price high:  2. 07   143. 40   163. 16  
1-yr high:  5. 08   124. 30   142. 77  
last close:  1. 36   101. 85   127. 84  
50-day avg:  1. 04   98. 27   122. 46  
200-day avg:  2. 51   99. 72   122. 70  
1-yr low:  0. 71   78. 19   100. 16  
volume:  502. 96 K 2. 38 M 4. 64 M
50-day avg volume:  864. 74 K 3. 31 M 4. 94 M
200-day avg volume:  850. 58 K 3. 23 M 4. 28 M

1-day return:  -1. 45 % 0. 22 % 0. 48 %
this week return:  10. 57 % 1. 77 % 2. 01 %
12-wk return:  49. 45 % 6. 56 % 3. 33 %
52-wk return:  -65. 67 % -2. 23 % 14. 35 %

enterprise value (EV):  300. 25 M 55. 17 B 104. 51 B
market cap:  25. 75 M 49. 01 B 96. 46 B
EBITDA:  -60. 98 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -4. 92   -91. 79   2. 29  
enterprise/revenue (EV/R):  2. 33   29. 84   23. 39  
total revenue:  128. 63 M 11. 28 B 40. 22 B
total debt:  303. 40 M 13. 73 B 16. 57 B
net income (common):  -113. 47 M 2. 37 B 3. 58 B

shares outstanding:  18. 93 M 607. 99 M 1. 22 B
shares:  7. 94 M 605. 53 M 1. 15 B
shares short:  400. 77 K 11. 62 M 12. 55 M
shares short prior month:  620. 54 K 11. 95 M 13. 44 M
short ratio:  2. 04   4. 82   3. 10  
short % of float:  3. 62 % 6. 19 % 2. 82 %
total cash/share:  1. 45   12. 02   11. 46  
total cash:  27. 38 M 7. 41 B 7. 37 B
free cash flow:  -55. 01 M 95. 99 M 2. 04 B
operating cash flow:  -62. 05 M 164. 74 M 3. 04 B

book value:  -3. 67   14. 43   28. 26  
price/book:  -0. 37   -1. 57   -2. 97  
gross profits:  61. 22 M 8. 28 B 18. 09 B
operating margins:  -48. 91 % -458. 01 % -642. 83 %
EBITDA margins:  -47. 41 % 13. 81 % 22. 47 %
profit margins:  -88. 21 % 6. 57 % 9. 92 %
gross margins:  54. 34 % 49. 33 % 54. 53 %

1-yr max volatility:  76. 06 % --- ---
1-yr mean volatility:  -0. 14 % 0. 01 % 0. 06 %

1-yr EPS:  -6. 05   3. 03   4. 09  
forward EPS:  -3. 64   4. 33   6. 99  
P/E:  -0. 22   6. 11   26. 91  
forward P/E:  -0. 37   8. 38   10. 48  
PE/G:  -0. 04   0. 37   5. 61  
growth:  5. 80 % 683. 72 % 104. 79 %
earnings high:  -0. 90   1. 27   1. 66  
earnings avg:  -0. 90   1. 01   1. 53  
earnings low:  -0. 90   0. 76   1. 40  
revenue high:  40. 90 M 2. 86 B 11. 19 B
revenue avg:  40. 90 M 2. 78 B 10. 84 B
revenue low:  40. 90 M 2. 67 B 10. 64 B
return on assets:  -10. 73 % -3. 27 % 3. 81 %
revenue growth:  5. 80 % 648. 36 % 97. 70 %
revenue/share:  6. 86   14. 68   59. 83  

beta (1yr vs S&P500):  0. 30   1. 21   0. 93  
sharpe (1yr):  -0. 28   0. 06   0. 98  

held % insiders:  12. 20 % 6. 46 % 3. 21 %
held % institutions:  76. 18 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : NVLN
.        + 0 =             0 :: INITIAL WEIGHT
.  + 439.511 =       439.511 :: inverse volume-to-price addition
.  + 176.164 =       615.675 :: spline projection addition
.  - 232.697 =       382.978 :: poor performance penalty
.    x 0.579 =       221.672 :: one-year gains+dividend factor
.    x 8.638 =      1914.716 :: 13 weeks' performance factor
.    x 1.492 =      2857.693 :: industry recommendation factor
.    x 1.142 =      3262.321 :: symbol recommendation factor
.    x 1.078 =      3517.525 :: EV/R factor
.    x 0.999 =      3513.752 :: return on assets factor
.    x 2.199 =      7726.761 :: revenue growth factor
.     x 2.04 =      15758.87 :: current ratio factor
.     x 1.44 =     22691.388 :: quick ratio factor
.    x 1.221 =     27700.192 :: short ratio factor
.    x 1.996 =     55297.707 :: price-to-book factor
.    x 1.245 =     68869.718 :: 5-day avg > 50-day avg
.    x 2.176 =    149866.288 :: P/E weight
.    x 2.209 =    331048.502 :: PE/G factor
.    x 1.397 =    462449.272 :: beta factor
.    x 0.277 =    127929.381 :: sharpe factor
.    x 1.777 =    227317.102 :: target low factor
.    x 1.241 =    282027.376 :: target mean factor
.    x 1.072 =    302390.729 :: target high factor
.    x 1.066 =    322231.434 :: industry 12-weeks return
.    x 0.962 =    310081.303 :: "drift" penalty 4 days ago
.    x 0.998 =    309576.994 :: overall "drift" factor
.    x 0.239 =     74124.052 :: largest single-day jump factor
.    x 0.063 =      4685.465 :: low price factor
.      x 1.0 =      4685.779 :: factor hist industry gain for week 06
.   cubeRoot =        16.734 :: reduced for readability
.                     16.734 :: FINAL WEIGHT for NASDAQ:NVLN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org